Chinese mainland offers support to HKSAR on COVID-19 control
SHENZHEN, Feb. 18 (Xinhua) -- A senior health official from the Chinese mainland has put forward instructive suggestions on the response to the latest resurgence of COVID-19 taken by the Hong Kong Special Administrative Region (HKSAR) at a video exchange meeting on Friday.
Wang Hesheng, deputy head of the National Health Commission, also introduced the mainland's experience in curbing locally-transmitted COVID-19 clusters at the meeting held between the mainland's work teams and HKSAR's anti-epidemic work team.
During the meeting, the five working groups from the mainland and their counterparts from the HKSAR briefed each other on the progress of their respective work.
They also coordinated their work on the most urgent tasks in HKSAR's fight against COVID-19, including improving nucleic acid testing capacity, increasing admission rates, reducing mortality rates, establishing makeshift hospitals, and providing medical supplies and daily necessities.
The current epidemic situation in Hong Kong is complicated and challenging, and both sides should maintain close communication, strengthen cooperation and act quickly to ensure that all anti-epidemic measures are effective, said the meeting.
Photos
- Gu wins women's free ski halfpipe, her second gold for China at Beijing 2022
- Beijing 2022 mascot Bing Dwen Dwen rises as an Olympic star as irresistibly cute design wins widespread acclaim
- In pics: Battle of the Flowers parade of 2022 Nice Carnival
- Shcherbakova wins as ROC duo finish 1-2 in women's singles figure skating at Beijing 2022
Related Stories
- Various sectors in Hong Kong gear up to take anti-epidemic measures
- 6.23 million more COVID-19 vaccine doses administered on Chinese mainland
- Chinese mainland reports 40 new local COVID-19 cases
- NHC fully supports Hong Kong in countering COVID-19 outbreak
- Domestic violence shelter in U.S. city says cases more severe during pandemic: report
- Chinese COVID-19 vaccine V-01 protects against Omicron in booster trial
Copyright © 2022 People's Daily Online. All Rights Reserved.